Medacta Group SA · SIX:MOVE
Medacta Group SA — FY2020 Earnings Presentation
11 slides from Medacta Group SA's earnings presentation, Jan 21, 2021
Slide 1: FY 2020 Preliminary Unaudited Top-Line Figures
FY 2020 Preliminary Unaudited Top-Line Figures 21 January 2021
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou
Slide 3: Medacta continues to outperform the market with strong 2H 2020 revenue acceleration
Medacta continues to outperform the market1 with a strong revenue acceleration in the second semester 20202 FY 2020 revenues were €302.5 million, only -2.1% on a constant currency basis, -2.6% reported vs 2019 2H revenues to €167.7 million, +7.6% on a constant currency basis, largely compensatin
Slide 4: 1H – 2H: Revenue Trend
1H – 2H: Revenue1 Trend (€m) -2.1% -2.6% +7.6% -12.2% 2H revenues largely compensating 1H results 2H acceleration sustained by both pent-up demand and new customers acquired Starting at the end of October the backlog recovery was limited by Covid-19 second Notes: wave 1. Unaudited figures 4
Slide 5: 1H – 2H: Revenue Growth Comparison by Product Line
1H – 2H: Revenue1 Growth Comparison by Product Line 1H Growth (%)2 2H Growth (%)2 -17.5% Hip Hip 5.6% -13.0% Knee Knee 4.1% Extremities3 41.7% Extremities 3 50.3% Spine 11.9% Spine 16.6% -12.2% 1H20 CC Growth 7.6% 2H20 CC Growth Since June the growth was driven by backlog recovery and acquisition
Slide 6: 1H – 2H: Revenue Growth Comparison by Geographic Area
1H – 2H: Revenue1 Growth Comparison by Geographic Area 1H Growth (%)2 2H Growth (%)2 -17.3% Europe Europe 6.3% -14.3% NA NA 11.0% APAC 5.8% APAC 12.0% -28.4 RoW -29.9% RoW 7.6% 2H20 CC Growth -12.2% 1H20 CC Growth In Europe and NA the backlog recovery was limited by Covid-19 second wave starting i
Slide 7: FY Revenue Bridge by Product Line
FY Revenue1 Bridge by Product Line (€m) -6.1% -4.1% 46.6% 14.6% (€m) 14.3; 28.9; 5% 9% 153.1; 106.2; 51% 35% 2 Hip Knee Extremities Spine Core business (Hip and Knee) was affected by postponement of elective procedures in 1H, partially compensated by an effective backlog recovery The Extremities
Slide 8: FY Revenue Bridge by Geographic Area
FY Revenue1 Bridge by Geographic Area (€m) -6.0% -1.0% 9.2% -29.2% (€m) 8.5; 3% 72.0; 24% 129.3; 43% 92.7; 30% Europe NA APAC ROW In Europe the most affected markets were France, Italy and Belgium; the “DACH” area recorded the smallest impact with Germany growing over the prior year In NA our in
Slide 9: Conclusions
Conclusions Covid-19 pandemic continues to determine uncertainty across all geographies The orthopaedic market confirmed its resilience with a pent-up demand following lockdown periods Medacta’s well balanced global geographic presence and product mix positioning allow to benefit in terms of d
Slide 10: Q&A
Adedacta Q&A
Slide 11: Medacta International
Adedacta Adedacta International